Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BCellMax Life 〉LBx-Liquid Biopsy

LBx-Liquid Biopsy

LBx-Liquid Biopsy

Liquid Biopsy is genomic testing on a sample collected via a routine blood draw, to aid in the selection of the right therapy for your patient diagnosed with cancer.

Request for Collaboration
CellMax LBx Is Indicated For Patients With Cancer

1.At Diagnosis
To look for treatable alterations (EGFR mutations) associated with Targeted (erlotinib) or Immunotherapy (pembrolizumab).
  • When tissue is insufficient or unavailable for genomic profiling
  • When only limited gene testing (NCCN-incomplete) is available
30%~50% of lung cancer biopsies have insufficient/unavailable tissue for comprehensive genomic profiling.
11%~18% is the frequency of the guideline-recommended alterations in NSCLC that are EXCLUDED in limited gene tests.

References :
1. Thompson et al, 2016. Clinical Cancer Research. Villaflor et al, 2016. Oncotarget. Hegemann et al, 2015. Cancer.
2. Compared to a test that only includes EGFR hotspots (L858R and Exon 19 deletion) and ALK fusions. Based on a population frequency in NSCLC for the following alterations associated with guideline-recommended alterations- 5% for EGFR G719A,  G719S, G719C and S768I mutations, 1% for ROS-1 fusions, 1% for RET fusions, 1-3% for BRAF mutations, 2-4% for HER2 mutations, and 1-4% for MET amplifications. Lovly, C., L. Horn, W. Pao. 2016. Molecular Profiling of Lung Cancer. My Cancer Genome.    

2. At Progression
To look for newly acquired alterations e.g.' resistance alterations to 1st and 2nd line treatment.
  • Instead of tissue to avoid invasive repeat biopsy
  • Instead of tissue to detect alterations that may be missed by tissue testing due tumor heterogeneity
Acquired resistance alterations e.g., EGFR T790M, may be present only in a fraction of tissue cells “due to” tumor heterogeneity.

Targetable Alterations Detectable By Repeated Testing at Progression...

EGFR T790M mutations, present in 50% of NSCLC patients with resistance to TKIs.
BRAF mutations present in 11~13% of metastatic colorectal cancer patients with acquired resistance to cetuximab.
Her2 receptor status changes occuring in ~15% of breast cancer patients during tumor progression.
References :
3. Kobayashi et al, 2005. New England Journal of Medicine. Pao et al, 2005, PLoS Med.
4. Fribbens et al, 2016. Journal of Clinical Oncology. Toy et al, 2013. Nature Genetics.
5. Lindstrom et al, 2012.  Journal of Clinical Oncology. Tzeng et al, 2017 Case Reports in Oncology.

CellMax LBx covers all NCCN Guidelinerecommended alterations and more In Cancer


Collaboration Options
Marketing & Distribution
More Information
People who like this also like
  • Pemetrexed Lyo Inj.Pemetrexed Lyo Inj.
  • MPB1734: an anti-cancer Nano Micelle drugMPB1734: an anti-cancer Nano Micelle drug
  • Absorbable Adhesion BarrierAbsorbable Adhesion Barrier
  • Altratene® β-Carotene ProductsAltratene® β-Carotene Products
  • Delcopan SRDelcopan SR
  • Comprehensive Genomic Profiling ServiceComprehensive Genomic Profiling Service
  • Anscare SIMO Negative Pressure Wound Therapy (NPWT) SystemAnscare SIMO Negative Pressure Wound Therapy (NPWT) System
  • Lonine (Capsule 200mg)Lonine (Capsule 200mg)